Scott Rocklage is an American healthcare management specialist and the principal executive of 5 AM Ventures. Scott joined the company’s leadership team in 2004 after serving its venture partner for one year. Since 2002, 5 AM Ventures has grown into a venture capital company that specializes in spinouts and startup investments. The company also invests in companies that focus on biotechnology, drug development, medical technologies, and product discovery platforms.
As the managing partner of 5 AM Ventures, Scott oversees medical technologies with an emphasis on materials science, drug delivery, and imaging agents. He works with John Diekman, the founding partner and chair, Andrew Schwab, co-founder and managing partner, and Rebecca Lucia, the chief financial officer.
Before joining the executive team at 5 AM Venture Management, Scott was instrumental in the growth of several companies. These include EPIRUS Biopharmaceuticals and Amersham Health that he served as CEO. Cubist Pharmaceuticals also recorded an increase in its revenue as Scott served as its president for seven years. Scott was also acknowledged as the first CEO of the company when he was appointed in 1994. His executive expertise also benefited Nycomed Salutar and Catalytica Pharmaceuticals.
Board Membership Roles
Besides serving as an executive, Scott also provides several pharmaceutical companies with strategic planning insights as a member of the council. He joined the executive board of Cidara Therapeutics in 2013 as the chair. He has also been serving the same role in the board of Novira Therapeutics since 2012. With extensive knowledge and experience in health care management, Scott has been the director of Acheogen since 2004. He has also used his strategic leadership expertise in advising the boards of Relypsa, Pulmatrix, Kinestral, Semprus, and Miikana Therapeutics.
Scott Rocklage is the brains behind several patented-healthcare management innovations in the United States. He is also the writer of more than 100 publications that have been peer-reviewed and published in online and offline journals. The Food and Drug Administration agency certified several drugs that Scott developed. He attributes his successful executive and scientific research career to the Ph.D. in Chemistry that he earned from MIT.